Primary Lateral Sclerosis is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Primary Lateral Sclerosis (PLS) is a rare, progressive neurodegenerative disorder characterized by selective degeneration of the upper motor neurons (corticospinal tract) in the motor cortex. Unlike Amyotrophic Lateral Sclerosis (ALS) - /diseases/amyotrophic-lateral-sclerosis, PLS spares lower motor neurons, resulting in a distinct clinical phenotype with predominant spasticity and rigidity without muscle wasting or fasciculations[1].
Primary Lateral Sclerosis is a rare condition, accounting for approximately 2-3% of all motor neuron diseases[2]. The estimated annual incidence is 0.1-0.2 per 100,000 population[3]. PLS typically presents in middle to late adulthood, with a mean age of onset between 45-55 years[4]. There appears to be a slight male predominance, though this varies across studies[5]. Approximately 10-15% of patients initially diagnosed with PLS will eventually develop lower motor neuron involvement and be reclassified as having ALS[6].
PLS is characterized by selective degeneration of the corticospinal motor neurons located in the motor cortex (Brodmann areas 4 and 6)[7]. The pathophysiological hallmarks include:
The molecular pathogenesis of PLS involves several interconnected mechanisms:
Excitotoxicity: Excessive glutamate signaling leads to calcium-mediated neuronal damage through overactivation of NMDA and AMPA receptors[8].
Oxidative Stress: Increased reactive oxygen species (ROS) accumulation damages cellular proteins, lipids, and DNA in motor neurons[9].
Mitochondrial Dysfunction: Impaired mitochondrial energy metabolism contributes to neuronal vulnerability and ATP depletion triggering apoptosis[10].
Cytoskeletal Abnormalities: Disruption of axonal transport machinery, including tubulin acetylation defects and dynein/dynactin dysfunction, impairs trafficking of essential cellular components[11].
Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines that exacerbate neuronal injury[12].
While most cases of PLS are sporadic, approximately 5-10% are familial[13]. Known genetic associations include:
The clinical presentation of PLS evolves gradually over years, typically beginning in the legs and progressing upward[17]:
Spasticity: The hallmark feature, presenting as velocity-dependent increase in muscle tone with hyperreflexia[18]
Pseudobulbar Affect: Emotional lability with involuntary crying or laughing episodes[19]
Bradykinesia: Slowness of voluntary movement due to corticospinal involvement[20]
Fatigue: Early and prominent exercise intolerance[21]
The progression of PLS follows a characteristic pattern[22]:
| Stage | Features | Time Course |
|---|---|---|
| Early | Leg spasticity, gait difficulty | 0-3 years |
| Middle | Upper limb involvement, dysarthria | 3-7 years |
| Advanced | Severe disability, dysphagia, respiratory compromise | 7-15 years |
Key differentiating features include[23]:
The diagnostic criteria for PLS require[24]:
| Test | Purpose |
|---|---|
| MRI brain and spine | Rule out structural lesions, show corticospinal tract hyperintensity |
| EMG/NCS | Exclude lower motor neuron involvement, confirm preserved sensory responses |
| CSF analysis | Exclude inflammatory/infectious processes |
| Genetic testing | Consider in familial cases or early onset |
| PET imaging | May show hypometabolism in motor cortex |
Conditions to exclude include[25]:
Spasticity Treatment[26]:
Pseudobulbar Affect[27]:
Muscle Cramps and Pain:
While no therapies are FDA-approved specifically for PLS, emerging approaches target underlying pathophysiological mechanisms[28]:
Several therapeutic approaches are under investigation[29]:
Key areas of active investigation include[30]:
Brain-computer interfaces (BCIs) offer significant potential for patients with Primary Lateral Sclerosis, primarily for communication support and motor rehabilitation[31].
Research on PLS-specific BCI applications is limited, but studies on related motor neuron conditions demonstrate the potential. Motor imagery BCIs have shown efficacy in upper motor neuron disorders, with rehabilitation applications showing promise for spasticity management[32].
The prognosis for PLS is generally more favorable than ALS[33]:
Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis. Brain. 1992. ↩︎
Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis. Neurology. 2007. ↩︎
Iwata NK, Kwon Y, Kimura F, et al. Primary lateral sclerosis: Epidemiology. Rinsho Shinkeigaku. 2011. ↩︎
Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve. 2007. ↩︎
Zhai P, Paganoni P, Bruijn L. Primary lateral sclerosis: The search for a biomarker. J Neurol Sci. 2021. ↩︎
Chio A, Calvo A, Moglia C, et al. Population-based study of survival among patients with primary lateral sclerosis. Neurology. 2021. ↩︎
Konno H, Yamamoto T, Iwasaki Y, Iizuka H. Primary lateral sclerosis: Neuropathological features. Acta Neuropathol. 1986. ↩︎
Rothstein JD. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci. 1995. ↩︎
Beal MF. [Oxidatively modified proteins in aging and disease](https://doi.org/10.1016/S0891-5849(02). Free Radic Biol Med. 2002. ↩︎
Mattiazzi M, D'Aurelio M, Gajewski CD, et al. Mutated mitochondrial SOD2 and ALS. J Cell Biol. 2002. ↩︎
De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Therapeutic implications. Neuromolecular Med. 2009. ↩︎
McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002. ↩︎
Valdmanis PN, Dupre N, Bouchard JP, et al. Three families with primary lateral sclerosis. Neurology. 2007. ↩︎
Siddique N, Siddique T. Genetics of primary lateral sclerosis. Muscle Nerve. 2009. ↩︎
Durr A, Davoine CS, Paternotte C, et al. Phenotype of autosomal dominant spastic paraplegia linked to chromosome 2p. Neurology. 2000. ↩︎
Sepulveda-Falla D, Matschke J, Lagunoff M, et al. HTRA1 mutations cause primary lateral sclerosis. Ann Neurol. 2014. ↩︎
Gotkine M, Argov Z. [Clinical differentiation between primary lateral sclerosis and upper motor neuron predominant ALS](https://doi.org/10.1016/S0072-9752(07). Handb Clin Neurol. 2007. ↩︎
Young RR. Spasticity: A review. Neurology. 1994. ↩︎
Schiffer R, Pope LE. Pseudobulbar affect in neurological disorders. Nat Rev Neurol. 2006. ↩︎
Quinn C, Edmundson C, Wadden C, et al. Primary lateral sclerosis: A diagnostic challenge. J Neurol Sci. 2020. ↩︎
Lou JS, Benatar M, Weiss MD, et al. Fatigue in primary lateral sclerosis. Neurology. 2009. ↩︎
Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004. ↩︎
Pringle CE. Primary lateral sclerosis: A distinct clinical entity? Muscle Nerve. Muscle Nerve. 1999. ↩︎
Stark FM, Moosa S, Mak HK, et al. Primary lateral sclerosis: A reappraisal. J Neurol Sci. 2021. ↩︎
Younger DS, Lou XL, Adelman L, et al. [Adult-onset motor neuron disease: Differential diagnosis](https://doi.org/10.1016/S0022-510X(98). J Neurol Sci. 1998. ↩︎
Francisco GE, Kesar TM, Pero S. Optimizing pharmacologic management of spasticity. Phys Med Rehabil Clin N Am. 2021. ↩︎
Schiffer R, Pope LE. Review of pseudobulbar affect including a perspective on therapeutic trials. Postgrad Med. 2006. ↩︎
Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019. ↩︎
Benatar M, Wuu J, Andersen PM, et al. Design of a phase 3 trial of edaravone for primary lateral sclerosis. Ann Clin Transl Neurol. 2022. ↩︎
Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Nat Rev Neurol. 2009. ↩︎
Wolpaw JR, et al. Brain-computer interfaces for communication and control. Proceedings of the IEEE. 2004. ↩︎
Pichiorri F, et al. Brain-computer interface aids for the rehabilitation of stroke patients. Brain Stimulation. 2015. ↩︎
Wicks P, Abrahams S, Maki D, et al. Survival in primary lateral sclerosis. Neurology. 2007. ↩︎